NEL ASA | Cash Flow

Fiscal year is January-December. All values NOK Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
37,662.20
6,511.40
27,779.70
62,637.20
124,447.00
197,503
Depreciation, Depletion & Amortization
731.10
3,551.10
15,512.20
9,732.40
35,968.00
64,470
Other Funds
-
-
472.10
2,090.40
28,341.00
-
Funds from Operations
36,046.20
13,123.50
12,718.80
52,437.80
88,480.00
133,033
Changes in Working Capital
553.30
8,774.80
22,787.40
20,040.90
22,407.00
6,968
Net Operating Cash Flow
35,493.00
4,348.70
35,506.20
32,396.90
110,887.00
140,001
Capital Expenditures
-
-
580.70
44,506.40
71,899.00
Sale of Fixed Assets & Businesses
8.20
-
-
36.70
30,669.00
Purchase/Sale of Investments
-
-
-
15,737.20
8,822.00
Net Investing Cash Flow
8.20
37,494.60
83,762.90
60,207.00
219,272.00
Issuance/Reduction of Debt, Net
1,666.70
7,577.80
3,844.00
-
-
Net Financing Cash Flow
28,531.30
120,151.00
333,814.30
5,028.10
399,692.00
Net Change in Cash
6,953.40
87,005.10
214,545.10
87,575.70
69,533.00
Free Cash Flow
35,493.00
4,348.70
36,086.90
63,567.30
147,435.00
Net Assets from Acquisitions
-
37,494.60
83,182.20
-
169,220.00
Change in Capital Stock
30,198.00
112,573.20
337,186.00
7,118.50
428,033.00

About NEL ASA

View Profile
Address
Karenslyst allé 20
Oslo PS 0278
Norway
Employees -
Website http://www.nel-asa.com
Updated 07/08/2019
NEL ASA develops diagnostic tests for the early detection of diseases based on gene expression signatures in blood samples. It operates through the In vitro diagnostic (IVD) and hydrogen segments. The In vitro diagnostic segment consists of developing innovative and patient friendly IVD products for early detection of diseases.